pac-1
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2017 (NCT03332355)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Caspase-3INHIBITOR
CASP3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CCc1cccc(/C=N/NC(=O)CN2CCN(Cc3ccccc3)CC2)c1O- Mol. weight
- 392.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL591429 ↗
Also known as
- pac-1
- pac-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04589832 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2020 | Genentech, HealthPartners Institute, Hoosier Cancer Research Network, Midwest Melanoma Partnership, Vanquish Oncology, Inc. |
| NCT03332355 | Phase 1 | Oct 1, 2017 | University of Illinois at Chicago, Vanquish Oncology, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vanquish Oncology, Inc. | For profit | 2 | 1 | 2 | 2017 |
| Genentech | For profit | 1 | 0 | 1 | 2020 |
| HealthPartners Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Midwest Melanoma Partnership | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Illinois at Chicago | Academic/Hospital | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1